Company intelligence / Profile preview

Recludix Pharma

San Diego, California, United Statesrecludixpharma.com ↗
Ownership
Private
Employees
~55
Development stage
Preclinical
01

Overview

Recludix has demonstrated preclinical proof-of-concept for its oral small molecule inhibitors targeting the SH2 domains of STAT6 and STAT3. The lead program REX‑8756 (STAT6 inhibitor) shows high potency/selectivity in biochemical/cellular assays and efficacy in murine asthma models. REX‑7117 (STAT3 inhibitor) has shown strong efficacy in vivo versus JAK/TYK2 inhibition for inflammatory arthritis models. No human clinical data reported as of May 2025.

Therapeutic areas
GastroenterologyPulmonologyImmunologyDermatologyNeurology
Modalities
Small molecules (oral inhibitors)
Industry
Biotech
02

Drug pipeline

3 assets

REX-8756

Preclinical

2 more assets in the full pipeline.

Request access →
03

Partnerships

Sanofi – strategic collaboration on development/commercialization of oral STAT6 inhibitors with option for U.S. profit-sharing/co-promotion arrangement.

Beyond the preview

Go deeper on Recludix Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recludix Pharma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call